Nivolumab and ipilimumab combination therapy for melanoma efficacy, safety and clinical integration in metastatic and adjuvant settings.

Discov Oncol · 2026 · PMC13369082 · PMID 42168665

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The 12-month event-free survival (EFS) rate was 83.7% in the neoadjuvant combination arm versus 57.2% in the adjuvant nivolumab arm—a highly significant and clinically meaningful difference.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.